Discovery of 4-Amino-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)
作者:Tatiana McHardy、John J. Caldwell、Kwai-Ming Cheung、Lisa J. Hunter、Kevin Taylor、Martin Rowlands、Ruth Ruddle、Alan Henley、Alexis de Haven Brandon、Melanie Valenti、Thomas G. Davies、Lynsey Fazal、Lisa Seavers、Florence I. Raynaud、Suzanne A. Eccles、G. Wynne Aherne、Michelle D. Garrett、Ian Collins
DOI:10.1021/jm901788j
日期:2010.3.11
underwent metabolism in vivo, leading to rapid clearance and low oral bioavailability. Variation of the linker group between the piperidine and the lipophilic substituent identified 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as potent and orally bioavailable inhibitors of PKB. Representative compounds modulated biomarkers of signaling through PKB in vivo and strongly inhibited
蛋白激酶 B(PKB 或 Akt)是调节生长和存活的细胞内信号通路的重要组成部分。通过 PKB 的信号传导在癌症中经常失调,因此 PKB 抑制剂具有作为抗肿瘤剂的潜力。一系列 4-benzyl-1-(7 H -pyrrolo[2,3 - d ]pyrimidin-4-yl)piperidin-4- amines中亲脂取代的优化提供了 ATP 竞争性的纳摩尔抑制剂,具有高达 150-与密切相关的激酶 PKA 相比,PKB 抑制的选择性倍数。尽管在细胞检测中具有活性,但含有 4-amino-4-benzylpiperidines 的化合物在体内进行代谢,导致快速清除和低口服生物利用度。哌啶和亲脂取代基之间的连接基团的变化鉴定了 4-amino-1-(7H -pyrrolo[2,3 - d ]pyrimidin-4-yl)piperidine-4-carboxamides 作为 PKB 的有效和